Free Trial
NASDAQ:MDGL

Madrigal Pharmaceuticals Q4 2023 Earnings Report

Madrigal Pharmaceuticals logo
$437.85 +0.68 (+0.16%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$439.00 +1.15 (+0.26%)
As of 08/29/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Madrigal Pharmaceuticals EPS Results

Actual EPS
-$5.68
Consensus EPS
-$5.26
Beat/Miss
Missed by -$0.42
One Year Ago EPS
-$4.98

Madrigal Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Madrigal Pharmaceuticals Announcement Details

Quarter
Q4 2023
Time
Before Market Opens
Conference Call Date
Wednesday, February 28, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Madrigal Pharmaceuticals' Q3 2025 earnings is scheduled for Thursday, October 30, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Madrigal Pharmaceuticals Earnings Headlines

Biopharma and Energy Execs Lead Weekly Insider Buying
How high will gold surge?
Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and declared a historic event would send the yellow metal to $3,150. People laughed at him at the time, but he was off by just two days. Now, Sean has a shocking new prediction for gold … and reveals a little-known way to get ahead of this bull market.tc pixel
See More Madrigal Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Madrigal Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Madrigal Pharmaceuticals and other key companies, straight to your email.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals (NASDAQ:MDGL), a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

View Madrigal Pharmaceuticals Profile

More Earnings Resources from MarketBeat